Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: European Research Centre for Drug Discovery and Development - UNISI
Street 1: via aldo moro 2
Street 2:
City: Siena
Province: Siena
Post Code: 53100
Country: Italy
Phone: +390577234172
Organization Email:
Web Site:
Other Online Presence:

Focal Point Contact Information

Salutation: Ms
First Name: Sabina
Last Name: Parente
Title: Administrative assistant

Alternate Focal Point Contact Information

Salutation: Dr
First Name: Sandra
Last Name: Gemma

General Information

Board Constituency: Technical agencies
Is your organization legally registered in your country: Yes
If yes, please enter your registration number:
Organization Type - Primary: Academic / Research Institution
Organization Type - Secondary: None
Organization Description:
The European Research Centre for Drug Discovery &
Development ( is an EU network created in 2003 to promote drug
development research in the field of infectious diseases and others.
NatSynDrugs is the acronym of the European Research Centre for Drug Discovery and
Development, an international multidisciplinary research network that encompasses Universities
and Institutes that have a major commitment to the development of innovative drugs.
NatSynDrugs is constituted by core groups who have the knowledge and skills for each stage of
drug development: from basic molecular research through proof-of-principle to pre-clinical testing.
Each research group contributes complementary skills to the Centre to facilitate a complete drug
development programme.

NatSynDrugs since 2003 activated several research programmes and social networking activities in
collaboration with EU. Viral infections and malaria are well established research fields in the
Centre while just 2 years ago we started a large programme for the development of novel
antitubercular agents.

Skills and experience of NatSynDrugs researchers in drug development may lead to the identification of innovative drugs against TB through a close collaboration with partners at StopTB. In particular we are interested in Drug resistance and translating research from bench to bedside.
Do you know about the UNHLM declaration:

Specializations / Areas of Work

Research and Development

Other Organization Information

Total number of staff in your organization: 100 +
Number of full-time staff who are directly involved with TB: 11 - 25
Number of part-time staff who are directly involved with TB: 1 - 5
Number of volunteers who are directly involved with TB: 0
How did you hear about the Stop TB Partnership: Internet search
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Involvement in Stop TB Working Groups
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: No
Please tell us how your organization is contributing to your country's national TB control plan:
We are working on novel targets for the control of TB infection

Geographical Reach

Which country is your headquarters located in: Italy
Which countries do you do operate in:
(This includes countries you are conducting activities in)


Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

New TB Drugs:
We are working on novel targets in order to develop potential drug candidates with innovative mechanisms of action able to combat the TB infection. One of our research topics is the development of inhibitors of the enzyme Zmp1, that is involved in the inhibition of inflammasome activation. We are also studying, through computational techniques and synthesis of specific ligands, the enzymes RpfB and RipA which are involved in the virulence of the Mycobacterium within the host.


Declaration of interests:
No conflicts of interest were delacred.

Application date: June 11, 2010
Last updated: June 25, 2012